摘要:
Substituted imidazoline derivatives corresponding to Formula I: a method for producing them from substituted aldehyde compounds of Formula B: and the use of such imidazoline derivatives and aldehyde compounds to treat pain, depression, urinary incontinence, diarrhea, pruritus, alcohol and drug misuse, drug dependency, lethargy and/or anxiety.
摘要:
Substituted oxadiazole compounds corresponding to formula I: in which X denotes CH, CH2, CH═CH, CH2CH2, CH2CH═CH or CH2CH2CH2; R1 denotes aryl or heteroaryl, in each case unsubstituted or mono- or polysubstituted; or a C1-3 alkyl group-linked aryl or heteroaryl group, in each case unsubstituted or mono- or polysubstituted; R2 denotes aryl or heteroaryl, in each case unsubstituted or mono- or polysubstituted; a C1-3 alkyl chain-attached aryl group, in each case unsubstituted or mono- or polysubstituted; and R3 and R4 independently denote H; C1-6 alkyl, in each case saturated or unsaturated, branched or unbranched, wherein R3 and R4 do not simultaneously mean H; or R3 and R4 together denote CH2CH2OCH2CH2, or (CH2)3-6. The compounds have an affinity for the μ-opioid receptor and may take the form of the racemate; enantiomers, diastereomers, mixtures of enantiomers or diastereomers, an individual enantiomer or diastereomer, a free base, or a salt with a physiologically acceptable acid.
摘要翻译:对应于式I的取代的恶二唑化合物:其中X表示CH,CH 2,CH-CH,CH 2 CH 2,CH 2 CH-CH或CH 2 CH 2 CH 2; R 1表示芳基或杂芳基,在每种情况下是未取代的或单取代或多取代的; 或者C 1-3烷基连接的芳基或杂芳基,在各种情况下是未取代的或单取代或多取代的; R 2表示芳基或杂芳基,在各种情况下为未取代或单取代或多取代; 在各种情况下为未取代或单取代或多取代的C 1-3烷基链连接的芳基; R3和R4独立地表示H; C 1-6烷基,各自为饱和或不饱和的,支链或非支链的,其中R3和R4不同时表示H; 或者R 3和R 4一起表示CH 2 CH 2 OCH 2 CH 2或(CH 2)3-6。 这些化合物对μ-阿片受体具有亲和力,并且可以采取外消旋体的形式; 对映体,非对映异构体,对映异构体或非对映异构体的混合物,单独的对映异构体或非对映体,游离碱或与生理上可接受的酸的盐。
摘要:
Substituted 5-aminomethyl-1H-pyrrole-2-carboxylic acid amides, a process for the production thereof, pharmaceutical preparations containing these compounds and the use of these compounds in pharmaceutical preparations for treatment or inhibition of withdrawal symptoms, memory disorders, neurodegenerative diseases, epilepsy, cardiovascular disorders, water retention, intestinal motility disorders, urinary incontinence, anorexia, tinnitus, pruritus, depression, sexual dysfunction, airways diseases, food intake disorders, or type II (non-insulin-dependent) diabetes, or for anxiolysis, diuresis, suppression of the urinary reflex, reducing the addictive potential of opioids, modulating locomotor activity, influencing the cardiovascular system, or regulating electrolyte balance.
摘要:
Substituted 2,5-diaminomethyl-1H-pyrroles, a process for the production thereof, pharmaceutical compositions containing them, and the use of these compounds for regulating 5-hydroxytryptamine uptake, noradrenalin uptake and/or opioid receptor activity, or for treating or inhibiting disorders or diseases at least partially mediated by a receptor selected from the group consisting of 5-hydroxytryptamine receptors, noradrenalin receptors and opioid receptors.
摘要:
Substituted 4-aminocyclohexanols, methods of producing the same, pharmaceuticals containing these compounds, the use of substituted 4-aminocyclohexanols for producing pharmaceutical compositions for the treatment of various indications, in particular pain, and for related treatment methods.
摘要:
Oxyalkyne compounds corresponding to the formula I ##STR1## in which the substituent Y in the meta- or para-position is R.sup.1 represents CH.sub.3 or NH.sub.2, R.sup.2 represents H or CH.sub.3, R.sup.3 represents H, C.sub.1-3 -alkyl or COCH.sub.3, and Ar represents an aromatic residue selected from the group ##STR2## with the proviso that the substituents R.sup.4, R.sup.5 and R.sup.6 are the same or different and each substituent represents H, F, Cl, Br, C.sub.1-6 -alkyl, CF.sub.3 or C.sub.1-6 -alkoxy, and R.sup.7 represents H, F, Cl, Br, C.sub.1-3 -alkyl or CF.sub.3,in the form of their racemates or mixtures of diastereoisomers or in optically active form, which are suitable active ingredients in pharmaceutical compositions.